Acromegaly disease activity according to ACRODAT®, a cross-sectional study in Spain: ACROVAL study.
ACRODAT®
AcroQoL
Acromegaly
Disease Activity
IGF-I
PASQ
Quality of life
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
15
06
2021
accepted:
04
10
2021
pubmed:
21
10
2021
medline:
24
3
2022
entrez:
20
10
2021
Statut:
ppublish
Résumé
To evaluate disease activity status using the Acromegaly Disease Activity Tool (ACRODAT Multicenter, observational, descriptive and cross-sectional study. Disease activity was assessed in adult patients with acromegaly under pharmacological treatment during at least 6 months using ACRODAT According to ACRODAT
Identifiants
pubmed: 34668173
doi: 10.1007/s12020-021-02900-0
pii: 10.1007/s12020-021-02900-0
pmc: PMC8816757
doi:
Substances chimiques
Insulin-Like Growth Factor I
67763-96-6
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
525-536Informations de copyright
© 2021. The Author(s).
Références
S. Melmed, M.D. Bronstein, P. Chanson, A. Klibanski, F.F. Casanueva, J.A.H. Wass et al. A consensus statement on acromegaly therapeutic outcomes. Nat. Rev. Endocrinol. 14(9), 552–61. (2018)
doi: 10.1038/s41574-018-0058-5
L. Vilar, C.F. Vilar, R. Lyra, R. Lyra, L.A. Naves, Acromegaly: clinical features at diagnosis. Pituitary. 20(1), 22–32 (2017)
doi: 10.1007/s11102-016-0772-8
A. Colao, D. Ferone, P. Marzullo, G. Lombardi, Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 25(1), 102–152 (2004)
doi: 10.1210/er.2002-0022
I.M. Holdaway, M.J. Bolland, G.D. Gamble, A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol. 159(2), 89–95 (2008)
doi: 10.1530/EJE-08-0267
C. Rajasoorya, I.M. Holdaway, P. Wrightson, D.J. Scott, H.K. Ibbertson, Determinants of clinical outcome and survival in acromegaly. Clin. Endocrinol. (Oxf) 41(1), 95–102 (1994)
doi: 10.1111/j.1365-2265.1994.tb03789.x
Y. Jackson, E. Flood, S. Rhoten, E.M. Janssen, M. Lundie, AcroVoice: eliciting the patients’ perspective on acromegaly disease activity. Pituitary. 22(1), 62–69 (2019)
doi: 10.1007/s11102-018-00933-9
H. Kepicoglu, E. Hatipoglu, I. Bulut, E. Darici, N. Hizli, P. Kadioglu, Impact of treatment satisfaction on quality of life of patients with acromegaly. Pituitary. 17(6), 557–563 (2014)
doi: 10.1007/s11102-013-0544-7
J. Tiemensma, A.A. Kaptein, A.M. Pereira, J.W. Smit, J.A. Romijn, N.R. Biermasz, Affected illness perceptions and the association with impaired quality of life in patients with long-term remission of acromegaly. J. Clin. Endocrinol. Metab. 96(11), 3550–3558 (2011)
doi: 10.1210/jc.2011-1645
R. Trepp, R. Everts, C. Stettler, S. Fischli, S. Allemann, S.M. Webb et al. Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL). Clin. Endocrinol. (Oxf) 63(1), 103–110 (2005)
doi: 10.1111/j.1365-2265.2005.02307.x
L. Katznelson, E.R. Laws Jr., S. Melmed, M.E. Molitch, M.H. Murad, A. Utz et al. Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(11), 3933–3951 (2014)
doi: 10.1210/jc.2014-2700
F. Cordido, J.A. Garcia Arnes, M. Marazuela Aspiroz, E. Torres Vela; grupo de Neuroendocrinologia de la Sociedad Espanola de Endocrinologia y N., [Practical guidelines for diagnosis and treatment of acromegaly. Grupo de Neuroendocrinologia de la Sociedad Española de Endocrinologia y Nutricion]. Endocrinol. Nutr. 60(8), 457 e1–e15 (2013)
doi: 10.1016/j.endonu.2013.01.012
S.J. Neggers, M.O. van Aken, W.W. de Herder, R.A. Feelders, J.A. Janssen, X. Badia et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J. Clin. Endocrinol. Metab. 93(10), 3853–3859 (2008)
doi: 10.1210/jc.2008-0669
M. Guitelman, A. Abreu, A.L. E-d-l-M, M. Mercado, Patient-focussed outcomes in acromegaly. Pituitary. 17(Suppl 1), S18–S23 (2014)
doi: 10.1007/s11102-013-0519-8
S.M. Webb, X. Badia, N.L. Surinach; Spanish AcroQol Study G., Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. Eur. J. Endocrinol. 155(2), 269–77 (2006)
doi: 10.1530/eje.1.02214
C. Sievers, K. Brubach, B. Saller, H.J. Schneider, M. Buchfelder, M. Droste et al. Change of symptoms and perceived health in acromegalic patients on pegvisomant therapy: a retrospective cohort study within the German Pegvisomant Observational Study (GPOS). Clin. Endocrinol. (Oxf) 73(1), 89–94 (2010)
P. Studenic, H. Radner, J.S. Smolen, D. Aletaha, Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum. 64(9), 2814–2823 (2012)
doi: 10.1002/art.34543
K. Webber, A.N. Davies, M.R. Cowie, Disparities between clinician and patient perception of breakthrough pain control. J. Pain Symptom Manage. 51(5), 933–937 (2016)
doi: 10.1016/j.jpainsymman.2015.12.309
A.J. van der Lely, R. Gomez, A. Pleil, X. Badia, T. Brue, M. Buchfelder et al. Development of ACRODAT((R)), a new software medical device to assess disease activity in patients with acromegaly. Pituitary. 20(6), 692–701 (2017)
doi: 10.1007/s11102-017-0835-5
X. Badia, S.M. Webb, L. Prieto, N. Lara, Acromegaly quality of life questionnaire (AcroQoL). Health Qual. Life Outcomes 2, 13 (2004)
doi: 10.1186/1477-7525-2-13
P.J. Trainer, W.M. Drake, L. Katznelson, P.U. Freda, V. Herman-Bonert, A.J. van der Lely et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med. 342(16), 1171–1177 (2000)
doi: 10.1056/NEJM200004203421604
S.M. Webb, X. Badia, Quality of life in acromegaly. Neuroendocrinology. 103(1), 106–111 (2016)
doi: 10.1159/000375451
A. Pokrajac, G. Wark, A.R. Ellis, J. Wear, G.E. Wieringa, P.J. Trainer, Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin. Endocrinol. (Oxf) 67(1), 65–70 (2007)
doi: 10.1111/j.1365-2265.2007.02836.x
A. Algeciras-Schimnich, D.E. Bruns, J.C. Boyd, S.C. Bryant, K.A. La Fortune, S.K. Grebe, Failure of current laboratory protocols to detect lot-to-lot reagent differences: findings and possible solutions. Clin. Chem. 59(8), 1187–1194 (2013)
doi: 10.1373/clinchem.2013.205070
P.U. Freda, M.B. Gordon, N. Kelepouris, P. Jonsson, M. Koltowska-Haggstrom, A.J. van der Lely, Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. Endocr. Pract. 21(3), 264–274 (2015)
doi: 10.4158/EP14330.OR
A.Giustina, A. Barkan, A. Beckers, N. Biermasz, B.M.K. Biller, C. Boguszewski, et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J. Clin. Endocrinol. Metab. 105(4), e937–e946 (2020).
doi: 10.1210/clinem/dgz096
A. Giustina, G. Barkhoudarian, A. Beckers, A. Ben-Shlomo, N. Biermasz, B. Biller et al. Multidisciplinary management of acromegaly: a consensus. Rev. Endocr. Metab. Disord. 21(4), 667–78. (2020)
doi: 10.1007/s11154-020-09588-z
I. Bernabeu, A. Pico, E. Venegas, J. Aller, C. Alvarez-Escola, J.A. Garcia-Arnes et al. Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY. Pituitary. 19(2), 127–137 (2016)
doi: 10.1007/s11102-015-0691-0
R. Camara, E. Venegas, J.A. Garcia-Arnes, F. Cordido, J. Aller, M.L. Samaniego et al. Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study. Pituitary. 22(2), 137–45. (2019)
doi: 10.1007/s11102-019-00943-1
M.J. van Esdonk, E.J.M. van Zutphen, F. Roelfsema, A.M. Pereira, P.H. van der Graaf, N.R. Biermasz et al. How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review. Pituitary. 21(3), 310–22. (2018)
doi: 10.1007/s11102-018-0884-4
C. Schofl, M. Grussendorf, J. Honegger, A. Tonjes, D. Thyroke-Gronostay, B. Mayr et al. Failure to achieve disease control in acromegaly: cause analysis by a registry-based survey. Eur. J. Endocrinol. 172(4), 351–356 (2015)
doi: 10.1530/EJE-14-0844
N.A. Tritos, A.F. Mattsson, G. Vila, B.M.K. Biller, A. Klibanski, S. Valluri et al. All-cause mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis. Eur. J. Endocrinol. 182(3), 285–92. (2020)
doi: 10.1530/EJE-19-0794
C. Schofl, H. Franz, M. Grussendorf, J. Honegger, C. Jaursch-Hancke, B. Mayr et al. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. Eur. J. Endocrinol. 168(1), 39–47 (2013)
doi: 10.1530/EJE-12-0602
M. Ragonese, S. Grottoli, P. Maffei, A. Alibrandi, M.R. Ambrosio, G. Arnaldi et al. How to improve effectiveness of pegvisomant treatment in acromegalic patients. J. Endocrinol. Invest. 41(5), 575–81. (2018)
doi: 10.1007/s40618-017-0773-0